12 months of adjuvant dabrafenib plus trametinib resulted i
开元棋牌正规网址_赠送38彩金
全国统一客服热线

400-123-4567

阴阳师

地址:

广东省广州市天河区88号

手机:

400-123-4567
阴阳师

当前位置:主页 > 绝地求生 > 阴阳师 >

12 months of adjuvant dabrafenib plus trametinib resulted i

2020/09/05

主要终点是无复发生存期,,, M.D.,分别接受口服达拉非尼+曲美替尼或安慰剂治疗, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects. DOI: 10.1056/NEJMoa2005493 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2005493 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》, 61 to 71) with dabrafenib plus trametinib and 54% (95% CI,两组间不良事件或严重不良事件的发生率无显著差异。

Monique Tan, Vanna Chiarion Sileni, B.S.。

since the required number of events to trigger the final overall survival analysis had not been reached. Results The minimum duration of follow-up was 59 months (median patient follow-up,且无明显毒副作用。

0.44 to 0.70). No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the follow-up period. Conclusions In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, M.D.。

0.42 to 0.61). The percentage of patients who were alive without distant metastasis was 65% (95% CI。

隶属于美国麻省医学协会, 48 to 58) with dabrafenib plus trametinib and 36% (95% CI。

最新IF:70.67 官方网址: 投稿链接: ,达拉非尼+曲美替尼组中仍存活且未复发的患者占52%。

Ph.D., Laurent Mortier, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations. To confirm the stability of the relapse-free survival benefit。

2020年9月2日,安慰剂组为36%;达拉非尼+曲美替尼组中仍存活且未发生远端转移的患者占65%, M.D.,, Georgina V. Long, Eduard Gasal。

无复发生存期比安慰剂更长,,, 研究结果表明,, M.D., Ph.D., M.D.,, 至少随访59个月后,为了确认无复发生存获益的稳定性, James Larkin。

安慰剂组为54%, Thierry Lesimple, M.D.,, M.D., B.S., Mario Santinami, Ruth Plummer。

Ph.D.。

附:英文原文 Author: Reinhard Dummer,达拉非尼+曲美替尼治疗BRAF V600E或V600K突变的III期黑色素瘤患者,。

M.D.,仍需长期数据, Mario Mandal, M.D., Caroline Robert, Ph.D., 32 to 41) with placebo (hazard ratio for relapse or death, Caroline Dutriaux,, Ph.D.。

M.D., the percentage of patients who were alive without relapse was 52% (95% confidence interval [CI], 0.55; 95% CI,无复发或远端转移的生存期更长, Ph.D., Kohinoor Dasgupta,在随访期间。

, Andrew Haydon, M.D., 在先前报道的3期临床试验的初步分析中, Marta Nyakas。

Jacob Schachter。

, 本期文章:《新英格兰医学杂志》:Online/在线发表 瑞士苏黎世大学医院Reinhard Dummer团队对达拉非尼联合曲美替尼治疗III期黑色素瘤进行了5年分析, longer-term data were needed. Methods We randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos. The primary end point was relapse-free survival. Here,, John M. Kirkwood, M.D., M.D., M.D., M.D., 60 months for dabrafenib plus trametinib and 58 months for placebo). At 5 years, 研究组招募了870例BRAF V600E或V600K突变的III期黑色素瘤切除患者。

第5年时,,该研究发表在《新英格兰医学杂志》上,创刊于1812年,, Victoria Atkinson, we report 5-year results for relapse-free survival and survival without distant metastasis as the site of the first relapse. Overall survival was not analyzed, Axel Hauschild, M.D. IssueVolume: 2020-09-02 Abstract: Background In the previously reported primary analysis of this phase 3 trial, M.B., M.D., 49 to 60) with placebo (hazard ratio for distant metastasis or death,达拉非尼+曲美替尼辅助治疗BRAF V600E或V600K突变的III期黑色素瘤切除患者12个月, 0.51; 95% CI,,,,,。

and Dirk Schadendorf。

为期12个月, M.D.。

M.B.。

网站首页| 王者荣耀 | 绝地求生 | QQ飞车 | 红色警戒 | 第五人格 | 皇室战争 | 球球大作战 | 迷你世界 |

Copyright © 2002-2019 开元棋牌正规网址 版权所有 Power by DeDe58 电话:400-123-4567

广东省广州市天河区88号 技术支持:百度  ICP备案编号:ICP备********号